(+)-VINCRISTINE
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Hoffmann-La RocheSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Diffuse Large B-Cell Lymphoma, Lymphoma Follicular cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Hoffmann-La Roche | Phase 1/2 | CCC |
Cyclophosphamide Hoffmann-La Roche | Phase 1/2 | CCC |
Zofran Hoffmann-La Roche | Phase 1/2 | CCC |
Atezolizumab Hoffmann-La Roche | Phase 1/2 | CCC |
Bendamustine Hoffmann-La Roche | Phase 1/2 | CCC |
Inno-206 Hoffmann-La Roche | Phase 1/2 | CCC |
Obinutuzumab Hoffmann-La Roche | Phase 1/2 | CCC |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Hoffmann-La Roche | Phase 1/2 | CCC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →